Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motixafortide + Cytarabine in Relapsed/Refractory AML
NCT01838395Phase 2Completed
- Sponsor
- BioLineRx Ltd.
- Start
- Apr 2013
- Primary completion
- Mar 2016
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 2, open-label trial of motixafortide in acute myeloid leukemia (AML) (6 arms), sponsored by BioLineRx Ltd. Primary endpoint: Safety and Tolerability at 6 weeks. Started Apr 2013; status: completed.
02
Drugs
motixafortide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01838395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01838395.